(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
25 August 2022 (25.08.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/178315 A1

(51) International Patent Classification:
C07D 403/12 (2006.01) *C07D 405/14* (2006.01)

(21) International Application Number:
PCT/US2022/017086

(22) International Filing Date:
18 February 2022 (18.02.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/151,605 19 February 2021 (19.02.2021) US

(71) Applicant: **MAZE THERAPEUTICS, INC.** [US/US]; 171 Oyster Point Blvd, Suite 300, South San Francisco, California 94080 (US).

(72) Inventors: **LEE, Patrick Sang Tae**; c/o Maze Therapeutics, Inc., 171 Oyster Point Blvd, Suite 300, South San Francisco, California 94080 (US). **EWING, Todd Jonathan August**; c/o Maze Therapeutics, Inc., 171 Oyster Point Blvd, Suite 300, South San Francisco, California 94080 (US). **REID, Adam Neil**; c/o Maze Therapeutics, Inc., 171 Oyster Point Blvd, Suite 300, South San Francisco, California 94080 (US). **SINZ, Christopher Joseph**; c/o Maze Therapeutics, Inc., 171 Oyster Point Blvd, Suite 300, South San Francisco, California 94080 (US). **ZHANG, Birong**; c/o Maze Therapeutics, Inc., 171 Oyster Point Blvd, Suite 300, South San Francisco, California 94080 (US). **BRONNER, Sarah M.**; c/o Maze Therapeutics, Inc., 171 Oyster Point Blvd, Suite 300, South San Francisco, California 94080 (US). **MORGANS, David John Jr.**; c/o Maze Therapeutics, Inc., 171 Oyster Point Blvd, Suite 300, South San Francisco, California 94080 (US). **HOEK, Maarten**; c/o Maze Therapeutics, Inc., 171 Oyster Point Blvd, Suite 300, South San Francisco, California 94080 (US). **ASSIMON, Victoria Anne**; c/o Maze Therapeutics, Inc., 171 Oyster Point Blvd, Suite 300, South San Francisco, California 94080 (US).


(74) Agent: **MCBRIAR, Mark D.** et al.; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, California 94304-1018 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(54) Title: APOL1 INHIBITORS AND METHODS OF USE



(A')

(57) Abstract: Provided herein are compounds of formula (A'): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X^1, X^2, X^3, X^4, R^a, R^b, R^c, L, Q, and Y are as defined herein. Also provided are methods of inhibiting APOL1 and methods of preparing compounds of formula (A'). Also provided are methods of inhibiting APOL1 and methods of treating an APOL1 -mediated disease, disorder, or condition in an individual.

WO 2022/178315 A1